



Geneviève Chêne, MD, PhD, is the Chief Executive of Santé publique France (www.santepubliquefrance.fr), the national agency for public health and Professor of Public Health.

Previously, she served as Director of the Bordeaux school of public health (ISPED, univ Bordeaux, 2017-19) and as the head of the department of public health at the Bordeaux university hospital (2011-19). In the field of public policy, she contributed to the preparation of the 2013-2017 national health strategy as a member of the “comité des sages” nominated by the prime minister, then as director of the Inserm Institute of Public Health between 2014 and 2017.

At the university of Bordeaux since 1999, Prof Chêne has taught clinical epidemiology and public health at the school of medicine and at the Bordeaux school of public health where she initiated an international distant-learning program (5000+ students since 2001).

As a researcher, she has established and led until 2015 an Inserm team on “HIV infections and associated morbidity”. Most cited works show how effects of antiretroviral therapy can be durable on the long term or contribute to the development of methodological innovations. Until 2019, she led EUCLID, a platform for international clinical trials that she created in 2014 within the F-CRIN infrastructure. This platform is involved in many international vaccine trials for the prevention of Ebola, malaria or pneumococcus. Since 2010, she is co-principal investigator of Memento, a national cohort of 2323 participants, with either cognitive complaints or light cognitive deficits, enrolled in French memory clinics and characterized through a multidimensional assessment of their risk factors and brain health.

Prof. Chêne is a member of the editorial advisory board of the Lancet Public Health and is associate editor of the European Journal of Epidemiology.